

Heikki Kuusanmäski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3306792/publications.pdf>

Version: 2024-02-01

29
papers

1,613
citations

840776

11
h-index

888059

17
g-index

30
all docs

30
docs citations

30
times ranked

2898
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401. | 9.4 | 73 |
| 2 | Endogenous and combination retinoids are active in myelomonocytic leukemias. <i>Haematologica</i> , 2021, 106, 1008-1021. | 3.5 | 11 |
| 3 | Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. <i>Science Advances</i> , 2021, 7, . | 10.3 | 28 |
| 4 | Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells. <i>Blood Advances</i> , 2021, 5, 1862-1875. | 5.2 | 5 |
| 5 | Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 71. | 5.4 | 12 |
| 6 | Identification of novel regulators of STAT3 activity. <i>PLoS ONE</i> , 2020, 15, e0230819. | 2.5 | 12 |
| 7 | Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 708-720. | 3.5 | 99 |
| 8 | Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819. | | 0 |
| 9 | Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819. | | 0 |
| 10 | Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819. | | 0 |
| 11 | Identification of novel regulators of STAT3 activity. , 2020, 15, e0230819. | | 0 |
| 12 | Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567. | 12.8 | 107 |
| 13 | Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry. <i>Human Mutation</i> , 2017, 38, 269-274. | 2.5 | 20 |
| 14 | Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. <i>Oncotarget</i> , 2017, 8, 22606-22615. | 1.8 | 13 |
| 15 | Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. <i>Oncotarget</i> , 2017, 8, 56338-56350. | 1.8 | 35 |
| 16 | Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. <i>Oncotarget</i> , 2017, 8, 97516-97527. | 1.8 | 28 |
| 17 | Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies. <i>Blood</i> , 2016, 128, 2921-2921. | 1.4 | 0 |
| 18 | In Silico and Ex Vivo Drug Screening Identifies Dasatinib as a Potential Targeted Therapy for T-ALL. <i>Blood</i> , 2016, 128, 4029-4029. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML. Blood, 2016, 128, 4711-4711. | 1.4 | 0 |
| 20 | Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood, 2015, 125, 639-648. | 1.4 | 229 |
| 21 | Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease. Blood, 2015, 126, 3006-3006. | 1.4 | 0 |
| 22 | Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells. Blood, 2015, 126, 700-700. | 1.4 | 0 |
| 23 | Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling. Blood, 2014, 124, 2160-2160. | 1.4 | 0 |
| 24 | Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. Blood, 2014, 124, 2046-2046. | 1.4 | 3 |
| 25 | Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma. Blood, 2014, 124, 646-646. | 1.4 | 0 |
| 26 | Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies. Blood, 2014, 124, 1771-1771. | 1.4 | 0 |
| 27 | Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood, 2013, 121, 4541-4550. | 1.4 | 252 |
| 28 | Novel Activating STAT5B Mutations As Drivers Of T-ALL. Blood, 2013, 122, 3863-3863. | 1.4 | 5 |
| 29 | Somatic <i>STAT3</i> Mutations in Large Granular Lymphocytic Leukemia. New England Journal of Medicine, 2012, 366, 1905-1913. | 27.0 | 681 |